uniQure N.V.
AMT-130
Huntington’s disease
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews AMT-130 for Huntington’s disease around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“The Company expects to provide a regulatory update after the receipt of official meeting minutes.”